Baumelou M - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome.

Baumelou M, Payssot A, Row C, Racine J, Lafon I, Bastie JN, Chevreux S, Chrétien ML, Maynadié M, Caillot D, Guy J. Baumelou M, et al. Br J Haematol. 2022 Jun;197(6):e82-e85. doi: 10.1111/bjh.18103. Epub 2022 Mar 11. Br J Haematol. 2022. PMID: 35277859 No abstract available.

Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group.

Gerhartz HH, Visani G, Delmer A, Zwierzina H, Ribeiro M, Jacobs A, Marcus R, Baumelou M, Fière D, Labar B, et al. Gerhartz HH, et al. Among authors: baumelou m. Bone Marrow Transplant. 1989 Dec;4 Suppl 3:36-7. Bone Marrow Transplant. 1989. PMID: 2697397 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2 results

Search Page

Filters